Amicus Therapeutics, Inc. (FOLD)
Pre-market:
| Previous close | 10.54 |
| Open | 10.40 |
| Bid | 10.16 x 600 |
| Ask | 10.19 x 400 |
| Day's range | 10.02 - 10.47 |
| 52-week range | 9.70 - 14.57 |
| Volume | |
| Avg. volume | 3,074,729 |
| Market cap | 3.012B |
| Beta (5Y monthly) | 0.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.51 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.75 |
Simply Wall St.When Will Amicus Therapeutics, Inc. (NASDAQ:FOLD) Become Profitable?
Amicus Therapeutics, Inc. ( NASDAQ:FOLD ) is possibly approaching a major achievement in its business, so we would like...
ZacksWhy Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GlobeNewswireAmicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today issued its fourth annual Environmental, Social, and Governance (ESG) report. This year’s report highlights the strength of the Company’s corporate responsibility structure including increased efforts towards transparency in our environmental reporting, our deep commitment to ensu
